Vetr downgraded shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a buy rating to a hold rating in a research report released on Monday. They currently have $86.44 target price on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on GILD. BidaskClub cut shares of Gilead Sciences from a buy rating to a hold rating in a report on Wednesday, August 9th. Deutsche Bank AG restated a buy rating and set a $81.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Cowen and Company restated an outperform rating and set a $90.00 price target on shares of Gilead Sciences in a report on Thursday, August 31st. Maxim Group restated a hold rating on shares of Gilead Sciences in a report on Monday, August 28th. Finally, Berenberg Bank restated a buy rating and set a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. Eleven equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $83.06.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 82.95 on Monday. The firm’s 50 day moving average is $75.14 and its 200 day moving average is $69.48. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $84.13. The company has a market cap of $108.33 billion, a PE ratio of 9.01 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business’s quarterly revenue was down 8.2% on a year-over-year basis. During the same period last year, the company posted $3.08 earnings per share. On average, equities analysts predict that Gilead Sciences will post $8.74 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/07/gilead-sciences-inc-gild-cut-to-hold-at-vetr-inc.html.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

In other news, EVP James R. Meyers sold 60,000 shares of the company’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the completion of the sale, the executive vice president now owns 62,715 shares of the company’s stock, valued at approximately $5,217,260.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $83.05, for a total transaction of $2,076,250.00. Following the completion of the sale, the executive vice president now directly owns 101,488 shares of the company’s stock, valued at approximately $8,428,578.40. The disclosure for this sale can be found here. In the last three months, insiders sold 414,999 shares of company stock valued at $32,335,540. Corporate insiders own 1.30% of the company’s stock.

Several institutional investors have recently made changes to their positions in GILD. Hall Laurie J Trustee raised its holdings in Gilead Sciences by 20.0% during the 1st quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Gilead Sciences by 583.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its holdings in Gilead Sciences by 19.4% in the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 267 shares in the last quarter. Penserra Capital Management LLC raised its holdings in Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares in the last quarter. Finally, Webster Bank N. A. raised its holdings in Gilead Sciences by 51.7% in the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 624 shares in the last quarter. 74.05% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.